The Latest Analyst Ratings for Vertex Pharmaceuticals
Portfolio Pulse from Benzinga Insights
Vertex Pharmaceuticals (NASDAQ:VRTX) has received a mix of bullish and indifferent analyst ratings over the last quarter, with no bearish ratings. Out of 16 analysts, 3 are bullish, 7 are somewhat bullish, and 6 are indifferent. The average price target is $382.31, representing an upside from the current price of $353.59. This target has increased by 3.86% over the past month. Analysts provide ratings based on research and forecasts, and these ratings are updated typically once a quarter.
December 11, 2023 | 2:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Vertex Pharmaceuticals has a positive outlook from analysts with an average price target of $382.31, suggesting an upside from the current price. The recent increase in the target price and absence of bearish ratings may contribute to a positive sentiment among investors.
The absence of bearish ratings and the presence of more bullish and somewhat bullish ratings indicate a positive sentiment towards VRTX. The increase in the average price target over the past month further reinforces this optimism. Given these factors, there is a likelihood of a positive short-term impact on VRTX's stock price.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100